Search results
Results from the WOW.Com Content Network
Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to ... they won a patent infringement ...
Name of the drug Synthesis mechanism Year that was Patented Governmental approval Patented expired Synthesis discoverer Year 1803–1805 [28] Morphine: Gates synthesis [29] 1952 1820: Quinine (isolation) Woodward and Doering: 1944 1830s Santonin: 1832: Chloral hydrate: Justus von Liebig: 1832 1833: Diastase: 1853 Acetylsalicylic acid (Aspirin ...
Four drugs from the class of direct Xa inhibitors are marketed worldwide. Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3]
The drugmaker is also expected to face revenue losses for two of its other top sellers, cancer immunotherapy Opdivo and blood thinner Eliquis, as they lose patent protection later this decade ...
Pfizer (NYS: PFE) careened off the patent cliff in more spectacular fashion than perhaps any other pharmaceutical company. The company lost U.S. patent protection for blockbuster cholesterol drug ...
Pfizer is still facing headwinds as it loses patent protection on key drugs in the years ahead, including Eliquis and Vyndaqel, but its diverse operations and focus on investing in growth ...
With time the law became successful in promoting the introduction of generics; in 1983 only 35% of top-selling branded drugs with expired patents had generic competition, and only 13% of prescriptions were for generics but in 2012, 84% of prescriptions in the US were filled with generic drugs.
Investors were reacting to news that ArQule's lead drug, ARQ 197, improved by 66% the median progression-free survival (PFS) of patients with advanced non-small-cell lung cancer. This cancer has ...